NASDAQ:EDIT - Editas Medicine Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $55.75
  • Forecasted Upside: 47.33 %
  • Number of Analysts: 16
  • Breakdown:
  • 4 Sell Ratings
  • 4 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$37.84
▼ -0.18 (-0.47%)

This chart shows the closing price for EDIT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Editas Medicine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDIT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDIT

Analyst Price Target is $55.75
▲ +47.33% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $55.75, with a high forecast of $86.00 and a low forecast of $14.00. The average price target represents a 47.33% upside from the last price of $37.84.

This chart shows the closing price for EDIT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 16 investment analysts is to hold stock in Editas Medicine. This rating has held steady since February 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 2 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 3 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 4 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 4 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 4 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 4 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 4 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/30/2021Chardan CapitalReiterated RatingBuy$75.00Medium
9/30/2021Stifel NicolausLower Price TargetHold$65.00 ➝ $46.00High
9/23/2021Stifel NicolausInitiated CoverageHold$65.00High
9/9/2021OppenheimerUpgradeMarket Perform ➝ Outperform$42.00 ➝ $80.00Medium
8/9/2021Truist FinancialUpgradeBuy$80.00Low
8/9/2021Truist SecuritiesUpgradeHold ➝ Buy$45.00 ➝ $80.00Medium
8/9/2021TruistUpgradeHold ➝ Buy$45.00 ➝ $80.00High
8/5/2021Evercore ISIUpgradeUnderperform ➝ Outperform$20.00 ➝ $60.00High
7/7/2021Chardan CapitalReiterated RatingBuyMedium
5/10/2021Morgan StanleyLower Price TargetUnderweight$40.00 ➝ $37.00High
5/3/2021Royal Bank of CanadaInitiated CoverageSector Perform$40.00High
4/16/2021The Goldman Sachs GroupInitiated CoverageSell$20.00High
3/22/2021Credit Suisse GroupInitiated CoverageOutperform$58.00High
3/8/2021BarclaysReiterated RatingOverweight ➝ Equal Weight$46.00Medium
3/2/2021Morgan StanleyLower Price TargetUnderweight$45.00 ➝ $40.00Medium
3/1/2021BarclaysDowngradeOverweight ➝ Equal Weight$46.00Low
2/28/2021JPMorgan Chase & Co.Reiterated RatingSell$30.00Low
2/26/2021TruistDowngradeBuy ➝ Hold$45.00Low
2/25/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$30.00Medium
2/10/2021Chardan CapitalBoost Price TargetBuy$55.00 ➝ $77.00Low
1/20/2021JPMorgan Chase & Co.Reiterated RatingHoldLow
1/19/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$64.00 ➝ $45.00Low
1/13/2021Wells Fargo & CompanyBoost Price TargetOverweight$69.00 ➝ $86.00Medium
1/7/2021Raymond JamesDowngradeOutperform ➝ Market PerformN/A
12/16/2020Morgan StanleyBoost Price TargetEqual Weight$30.00 ➝ $64.00Low
12/10/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$28.00 ➝ $69.00High
11/11/2020Morgan StanleyLower Price TargetEqual Weight$31.00 ➝ $30.00High
11/6/2020Raymond JamesLower Price TargetOutperform$65.00 ➝ $60.00Medium
11/2/2020Robert W. BairdInitiated CoverageUnderperform$14.00High
10/13/2020Morgan StanleyLower Price TargetEqual Weight$32.00 ➝ $31.00Medium
8/10/2020Morgan StanleyBoost Price TargetEqual Weight$27.00 ➝ $32.00Low
8/7/2020Raymond JamesBoost Price TargetOutperform$46.00 ➝ $65.00High
6/18/2020SunTrust BanksInitiated CoverageBuy$45.00High
6/15/2020OppenheimerReiterated RatingHoldHigh
6/12/2020Chardan CapitalReiterated RatingBuy$55.00High
5/11/2020Morgan StanleyLower Price TargetEqual Weight$30.00 ➝ $27.00High
5/7/2020OppenheimerInitiated CoverageHoldMedium
3/4/2020Chardan CapitalReiterated RatingBuy$55.00High
2/27/2020Raymond JamesLower Price TargetOutperform$44.00 ➝ $41.00High
2/27/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
2/21/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$28.00High
12/10/2019Chardan CapitalReiterated RatingBuy$55.00Low
8/9/2019Morgan StanleySet Price TargetHold$29.00High
7/25/2019Chardan CapitalReiterated RatingBuy$55.00Medium
6/16/2019Chardan CapitalSet Price TargetBuy$55.00Medium
5/8/2019OppenheimerReiterated RatingHoldMedium
4/11/2019Evercore ISIInitiated CoverageOutperformMedium
2/7/2019BTIG ResearchInitiated CoverageBuy$30.00Low
1/22/2019JPMorgan Chase & Co.Reiterated RatingHoldHigh
1/22/2019CowenReiterated RatingBuyMedium
1/22/2019Chardan CapitalReiterated RatingBuy$55.00High
1/10/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
12/31/2018SunTrust BanksReiterated RatingBuyHigh
10/9/2018GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
9/21/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$40.00High
8/6/2018JPMorgan Chase & Co.Set Price TargetHold$36.00High
5/15/2018Chardan CapitalLower Price TargetBuy$72.50 ➝ $55.00Low
3/14/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$28.00 ➝ $43.00Low
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$28.00 ➝ $46.00Medium
3/7/2018JMP SecuritiesBoost Price TargetOutperform$40.00 ➝ $67.00High
2/13/2018CLSAInitiated CoverageUnderperform ➝ UnderperformLow
1/23/2018SunTrust BanksUpgradeHold ➝ Buy$17.00 ➝ $45.00High
11/7/2017CowenReiterated RatingBuyN/A
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 ➝ $28.00N/A
9/6/2017BarclaysInitiated CoverageOverweight$19.69 ➝ $28.00Medium
8/9/2017JPMorgan Chase & Co.Set Price TargetHold$27.00High
7/18/2017OppenheimerMarket PerformN/A
7/13/2017SunTrust BanksInitiated CoverageHold ➝ Hold$17.00High
3/27/2017Chardan CapitalInitiated CoverageBuy ➝ BuyHigh
3/15/2017CowenReiterated RatingBuyLow
3/8/2017JPMorgan Chase & Co.Set Price TargetHold$32.00Low
2/19/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
2/15/2017Jefferies Financial GroupReiterated RatingBuy$35.00N/A
1/11/2017Jefferies Financial GroupSet Price TargetBuy$35.00N/A
12/12/2016Jefferies Financial GroupSet Price TargetBuy$35.00N/A
(Data available from 10/18/2016 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/20/2021
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/18/2021
  • 2 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
10/18/2021

Current Sentiment

  • 2 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Editas Medicine logo
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $37.84
Low: $37.40
High: $38.77

50 Day Range

MA: $56.30
Low: $35.61
High: $72.94

52 Week Range

Now: $37.84
Low: $27.12
High: $99.95

Volume

2,350 shs

Average Volume

2,009,000 shs

Market Capitalization

$2.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Editas Medicine?

The following Wall Street analysts have issued reports on Editas Medicine in the last year: Barclays PLC, Chardan Capital, Credit Suisse Group AG, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist, Truist Financial Co., Truist Securities, and Wells Fargo & Company.
View the latest analyst ratings for EDIT.

What is the current price target for Editas Medicine?

16 Wall Street analysts have set twelve-month price targets for Editas Medicine in the last year. Their average twelve-month price target is $55.75, suggesting a possible upside of 46.6%. Wells Fargo & Company has the highest price target set, predicting EDIT will reach $86.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $14.00 for Editas Medicine in the next year.
View the latest price targets for EDIT.

What is the current consensus analyst rating for Editas Medicine?

Editas Medicine currently has 4 sell ratings, 4 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EDIT, but not buy more shares or sell existing shares.
View the latest ratings for EDIT.

How do I contact Editas Medicine's investor relations team?

Editas Medicine's physical mailing address is 11 Hurley Street, Cambridge MA, 02141. The company's listed phone number is (617) 401-9000 and its investor relations email address is [email protected] The official website for Editas Medicine is www.editasmedicine.com.